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013 ASCO/CAP scoring criteria
a  b  s  t  r  a  c  t
It has been  proven  that  chromosome  17 centromere  (CEP17)  ampliﬁcation  causes  misleading  human
epidermal  growth  factor receptor  2 (HER2)  gene  ﬂuorescence  in  situ  hybridization  (FISH)  results,  pre-
cluding  anti-HER2-based  therapy  in some  patients  with  breast  carcinoma.  We  used  the 2013  American
Society  of  Clinical  Oncology/College  of  American  Pathologists  (ASCO/CAP)  scoring  criteria  to evaluate
HER2  ampliﬁcation  status  in  175  cases  of  breast  carcinoma  with  chromosome  17  polysomy.  We  used
immunohistochemistry  (IHC)  to determine  the  HER2  ampliﬁcation  status,  and  2-color  FISH  to  detect
CEP17,  and reviewed  the  results  of initial  evaluation  using  the  2007  ASCO/CAP  criteria.  Of  the  175 cases,
17,  95,  and  63  were  IHC  0/1+,  2+, and  3+, respectively.  Evaluation  of  IHC  HER2  status  according  to  the
2013  ASCO/CAP  criteria  identiﬁed  signiﬁcantly  more  HER2-positive  cases  compared  to cases  evaluated
using  the  2007  criteria  (p  <  0.05).  When  the FISH  results  were  evaluated  in parallel  with  the  2013  criteria,
we found  that 22  cases  were  not  HER2-negative  despite  the  presence  of polysomy  17, which,  according
to  the  2013  criteria,  indicates  HER2-positive  status.  Our  ﬁndings  indicate  that  in breast  carcinoma,  HER2
status  in  the presence  of  polysomy  17  may  vary  with  the  scoring  criteria  used.  In  turn,  performing  FISH
and  evaluating  samples  using  the  2013  ASCO/CAP  criteria  means  that more  patients  with breast  cancer
may  be appropriate  for targeted  treatment  with  trastuzumab,  potentially  improving  their  outcome.
©  2014  The  Authors.  Published  by  Elsevier  GmbH.  This  is an  open  access  article  under  the CCntroduction
Breast cancer is the most common cancer in women and the
econd most common cancer worldwide [1]. In the last decade,
argeted therapy in breast cancer has become part of routine
linical protocols all over the world. Trastuzumab, a humanized
onoclonal antibody that targets human epidermal growth factor
eceptor 2 (HER2), is routinely used to treat patients with breast
arcinoma who overexpress HER2 [2,3]; when combined with
hemotherapy in the metastatic setting, trastuzumab improves
rogression-free survival and overall survival by years [4]. Other
ER2-targeting drugs (e.g., the kinase inhibitor lapatinib [5],
he antibody pertuzumab [6], the antibody–drug conjugate ado-
rastuzumab emtansine [T-DM1] [7]) have been approved for use
n the treatment of HER2-positive metastatic breast cancer. At the
ame time, it has been shown that lapatinib (when added to pacli-
axel) [8] and pertuzumab (as a single agent) [9] offer no clinical
eneﬁt to patients with HER2-negative metastatic disease. HER2
ncodes a 185-kDa receptor tyrosine kinase, activating signaling
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pathways that stimulate cell proliferation and survival, including
the phosphatidylinositol 3-kinase/protein kinase B/mammalian
target of rapamycin (PI3K/Akt/mTOR) and mitogen-activated
protein kinase (MAPK) pathways [10]. Approximately 20% of
breast cancers overexpress HER2, caused by ampliﬁcation of
the erbB2 oncogene [11–14]. As a marker of aggressive disease,
HER2 overexpression is an independent predictor of decreased
recurrence-free survival, breast cancer-related survival, and overall
survival [15,16]. The development of HER2-targeting therapy has
revolutionized the treatment of HER2-positive breast cancer such
that we  may  consider HER2 overexpression a positive predictor of
improved outcome.
Studies worldwide have identiﬁed the signiﬁcant beneﬁt of
ﬁrst-line trastuzumab therapy in conjunction with surgery and
cytotoxic chemotherapy for treating HER2-positive breast car-
cinoma [17,18]. Thus, accurate HER2 testing to ensure that the
right patient receives the right treatment is now more critical than
ever [19–21]. Currently, we evaluate HER2 status mainly with
immunohistochemistry (IHC) or ﬂuorescence in situ hybridization
(FISH); IHC analysis is usually used as the primary assay, and
reﬂex FISH is performed for a speciﬁc subset of IHC results (e.g.,
1+ or 2+); other laboratories primarily use FISH [22,23]. The
2013 ASCO/CAP (American Society of Clinical Oncology/College
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f American Pathologists) guideline deﬁnes HER2-positive breast
arcinoma as tumors containing >10% of cells with complete and
ntense membrane staining by IHC. FISH-positive breast carcinoma
s deﬁned as average HER2 copy number ≥ 6.0 signals/cell or aver-
ge HER2 copy number ≥ 4.0 signals/cell and HER2/chromosome
7 centromere (CEP17) ratio ≥ 2.0 [24]. In comparison, the 2007
SCO/CAP guideline uses a cutoff value of HER2/CEP17 ratio > 2.2
o deﬁne HER2 overexpression [24–26]. The 2013 criteria beneﬁts
any more patients in terms of the targeted drugs they may
otentially receive, especially patients with chromosome 17
olysomy (polysomy 17) as identiﬁed by dual-probe FISH. In terms
f HER2 gene assessment, it has been proven that CEP17 ampli-
cation causes misleading HER2 FISH results [27–31], precluding
nti-HER2-based therapy for some patients. In this study, we used
he 2013 ASCO/CAP scoring criteria to evaluate HER2 ampliﬁcation
tatus in breast carcinoma with polysomy 17.
aterials and methods
atients
The study involved 175 cases with primary invasive breast
ancer. Samples were obtained after the patients had provided
nformed consent; the Nanjing Drum Tower Hospital Ethics Com-
ittee approved the study. The HER2 IHC was determined and we
eviewed the HER2 status of the archived samples, and analyzed
he tumors according to the 2007 and 2013 ASCO/CAP guidelines.
HC
Each tissue sample was ﬁxed immediately in 10% neutral
uffered formalin for 6–48 h, and then parafﬁn-embedded. Sections
4 m)  were deparafﬁnized routinely, rehydrated, and retrieved.
ER2 expression was detected using 1:300 polyclonal antibody
0485 (DakoCytomation, Glostrup, Denmark) overnight at 4 ◦C.
ositive and negative controls were run together with the test
ample. Using the 2007 ASCO/CAP criteria, HER2 expression was
cored as follows: 0 = no staining; 1+ = weak, incomplete mem-
rane staining in >10% of tumor cells; 2+ = weak to moderately
omplete membrane staining in >10% of tumor cells; 3+ = strong,
omplete membrane staining in >30% of tumor cells [24–26]. In
he 2013 ASCO/CAP scoring criteria, IHC 3+ = complete, intense
taining of >10% of tumor cells; IHC 2+ = circumferential, incom-
lete and/or weak/moderate membrane staining in >10% of tumor
ells or complete and circumferential intense membrane staining
n ≤10% of tumor cells; IHC 1+ = faint/barely perceptible incom-
lete membrane staining in >10% of tumor cells; IHC 0 = no staining
r incomplete and faint/barely perceptible membrane staining in
10% of tumor cells [24]. We  used the 2007 guidelines to evaluate
ER2 IHC.
ISH
Two-color FISH was performed on 2-m thick sections
rom formalin-ﬁxed, parafﬁn-embedded tissue sections from all
75 cases. Before hybridization, sections were deparafﬁnized,
ehydrated in 100% ethanol, and air-dried. Commercially avail-
ble, locus-speciﬁc HER2 probe (190-kb SpectrumOrange directly
abeled ﬂuorescent DNA probe) and CEP17 probe (5.4-kb Spectrum
reen directly labeled ﬂuorescent DNA) were used according to
he manufacturer’s recommendations (Jinpujia, Beijing, China). We
cored 30 nuclei per sample, and recorded the number of HER2
red) and CEP17 (green) signals according to the 2007 ASCO/CAP
riteria. Gene ampliﬁcation was indicated when the HER2/CEP17
atio > 2.2; ampliﬁcation was equivocal when 1.8 ≤ HER2/CEP17
atio ≤ 2.2, and negative when HER2/CEP17 ratio < 1.8 [24–26]. The Practice 211 (2015) 421–425
2013 ASCO/CAP criteria uses HER2/CEP17 ratio ≥ 2.0 (Fig. 1a and
b) or HER2/CEP17 ratio < 2.0 but average HER2 copy number ≥ 6.0
signals/cell (Fig. 1c) to indicate the mean HER2 ampliﬁcation for
20 cells. According to the 2013 guidelines, HER2/CEP17 ratio < 2.0
and average HER2 copy number ≥ 4.0 and <6 signals/cell indi-
cated equivocal ampliﬁcation (Fig. 1e and f); HER2/CEP17 ratio < 2.0
and average HER2 copy number < 4 signals/cell indicated nega-
tive ampliﬁcation (Fig. 1d) [24]. Polysomy 17 was  deﬁned as >1.86
CEP17 signals per nucleus [27–31].
Statistical analysis
A nonparametric chi-square test was used for testing asso-
ciations between variables and p values < 0.05 were considered
statistically signiﬁcant. Statistical analysis was performed using the
Statistical Package for Social Sciences software (v17.0; SPPS Inc.,
Chicago, IL).
Results
Clinicopathological characteristics of the cohort
All 175 patients were women, the age range was 31–78 years
(mean 53 years), and all patients had invasive breast carcinoma.
Comparison of IHC and FISH for HER2 status
More than half of the cases were IHC 2+ (95 cases, 54.3%). The
remaining cases included 17 IHC 0 or IHC 1+ cases (9.7%), and 63 IHC
3+ cases (36.0%). In the 17 IHC 0/1+ cases, 16 were HER2-negative by
FISH based on the 2007 ASCO/CAP guidelines; FISH determined that
one case was  HER2-equivocal. Of the 95 patients identiﬁed as IHC
2+, 61 were classiﬁed as HER2-non-ampliﬁed and 34 were HER2-
ampliﬁed according to the 2007 guideline. Of 63 IHC 3+ patients,
56 were HER2-ampliﬁed, and seven were HER2-negative by FISH.
In the IHC 2+ cases, FISH determined that a much larger propor-
tion was HER2-negative than HER2-positive (64.8% vs. 35.2%). We
obtained different results when we reevaluated HER2 status using
the 2013 ASCO/CAP scoring criteria. As shown in Table 1, there were
signiﬁcantly more HER2-positive cases, which were, in order of case
increases: IHC 2+ (from 34 to 43 cases, p < 0.05), IHC 3+ (from 56 to
60, p > 0.05), IHC 1+ (increase from 0 to 3, p < 0.05). There was  also
a signiﬁcant increase in HER2-equivocal cases, where IHC 2+ cases
increased from 0 to 5, followed by IHC 1+ cases. Correspondingly,
there were fewer HER2-non-ampliﬁed cases (Table 1).
Comparison between 2007 and 2013 ASCO/CAP guidelines for
FISH-derived HER2-negative status accompanied by polysomy 17
According to the 2007 ASCO/CAP guideline, HER2-positive sta-
tus by FISH was deﬁned as HER2/CEP17 ratio > 2.2, but based on the
2013 ASCO/CAP guideline, many HER2-non-ampliﬁed cases with
polysomy 17 should be redeﬁned, given that previously deﬁned
HER2-negative cases may  be deﬁned as HER2-ampliﬁed according
to the 2013 guideline. There was  polysomy 17 in 100 (57.1%) of
the 175 patients, of which 48 were deﬁned as HER2-non-ampliﬁed
based on the 2007 criteria. Using the criterion of ≥6 HER2 sig-
nals per nucleus to denote positive ampliﬁcation, 16 cases (33.3%)
were categorized as HER2-ampliﬁed. Of these, three, nine, and four
were IHC 0/1+, IHC 2+, and IHC 3+, respectively. We  observed ≥4
HER2 copies but <6 HER2 copies per nucleus in another six cases
(12.5% of 48 polysomy 17 cases) categorized as HER2-equivocal,
where one and ﬁve cases were IHC 0/1+ and IHC 2+, respectively.
Of the 48 HER2-non-ampliﬁed cases, 26 were persistently HER2-
non-ampliﬁed despite the CEP17 status (Table 2). Therefore, these
ﬁndings demonstrate that there was  discrepant interpretation of
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Fig. 1. FISH evaluation of HER2 status based on 2013 ASCO/CAP scoring criteria. (A and B) The 2013 ASCO/CAP criteria evaluate 20 tumor cells; a HER2/CEP17 ratio ≥ 2.0 is










Hopy  number < 4.0 signals/cell is deﬁned as HER2-negative. (E and F) Previous HER2
mpliﬁed. A HER2/CEP17 ratio < 2.0 and average HER2 copy number ≥ 4.0 and <6.0 
f  the references to color in this ﬁgure legend, the reader is referred to the web ver
ene ampliﬁcation status in 22 (12.6%) cases when the number of
EP17 copies was taken into account, and illustrates how breast
ancer with polysomy 17 can be interpreted as HER2-positive, -
quivocal, or -negative partly depending on which scoring method
s applied to interpret the HER2 FISH results.
able 1
ER2 FISH results based on 2007 and 2013 ASCO/CAP scoring criteria.
HER2 IHC results Cases 2007 scoring criteria 
0/1+ 17 Negative 
Equivocal 
Positive 
2+  95 Negative 
Equivocal 
Positive 
3+  63 Negative 
Equivocal 
Positive tive cases deﬁned based on the 2007 ASCO/CAP guideline were redeﬁned as HER2-
s/cell was  deﬁned as HER2-equivocal. Red, HER2; green, CEP17. (For interpretation
f the article.)
DiscussionUsing FISH, we investigated the frequency of polysomy 17 and
its association with HER2 alteration in patients with invasive breast
cancer.
2013 scoring criteria p
16 Negative 11 <0.05
1 Equivocal 2
0 Positive 3
61 Negative 47 <0.05
0 Equivocal 5
34 Positive 43
7 Negative 3 >0.05
0 Equivocal 0
56 Positive 60
424 X. Pu et al. / Pathology – Research and
Table 2
Analysis of HER2 FISH results of cases with polysomy 17 based on 2013 ASCO/CAP
scoring criteria.
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As polysomy 17 is relatively common in breast carcinoma, it
s possible that HER2 FISH results can be misinterpreted. In a
ecently published series, Vanden Bempt et al. reported that >40%
f breast carcinomas harbor increased CEP17 copy numbers [32].
n our study, there was polysomy 17 in 57.1% (100/175) of pri-
ary invasive breast carcinoma cases. In 52 patients, polysomy 17
ccompanied HER2 cluster ampliﬁcation; the remaining 48 cases
ere deﬁned as HER2-non-ampliﬁed based on the 2007 ASCO/CAP
uideline. Therefore, this led to many the patients with polysomy
7 but non-HER2 cluster ampliﬁcation losing the opportunity to
eceive targeted treatment. When we reevaluated the 48 cases
hat were HER2-non-ampliﬁed and polysomy 17-accompanied, we
ound that 16 and six cases could be deﬁned as HER2-ampliﬁed and
ER2-equivocal, respectively. Compared to other cases, polysomy
7 was much more common in IHC 2+ cases, which agrees the
ndings of others [27,28,30]. Subsequently, there was a signiﬁ-
ant increase in the number of HER2-ampliﬁed and HER2-equivocal
ases. Importantly, the majority of IHC 2+ cases, i.e., cases where
here was an increase from 34 to 43 patients, were responsive to
he targeted therapy, followed by the IHC 3+ cases; the reevaluation
lso improved the prospects for the IHC 0/1+ cases. In addition to
he 16 cases redeﬁned as HER2-ampliﬁed, redeﬁning the six cases
s HER2-equivocal means that these patients may  be able to receive
argeted treatment.
In our series, polysomy 17 was deﬁned as CEP17/nucleus
atio > 1.86 [27–31], and we believe that CEP17 represents chro-
osome 17, but the question of whether CEP17 copy number
ctually reﬂects the condition of polysomy 17 remained. In view
f this, determining HER2 ampliﬁcation status may  partly depend
n whether CEP17 copy number is taken into account. Indeed, 54.2%
f the cases harboring CEP17 did not have HER2 gene ampliﬁcation.
mportantly, the majority of these cases had a borderline IHC score
2+), and >75% of patients who were IHC 2+ were HER2-negative by
ISH. Therefore, these cases were not responsive to anti-HER2 tar-
eted therapy and did not ﬁt the category of HER2-ampliﬁed breast
arcinoma.
Another interesting issue of clinical relevance is whether
olysomy 17 is associated with clinical behavior similar to that of
ER2-ampliﬁed tumors. Many previous studies suggest that inde-
endently of HER2 ampliﬁcation status, the presence of CEP17
lterations identiﬁes a subset of breast cancer with more aggres-
ive biological and clinical behaviors that may  not respond to
onventional therapy [30,33–35]. In a recent study, Bartlett et al.
howed that the presence of polysomy 17, as established by CEP17
ISH, was predictive of response to anthracyclines [36]. There-
ore, it is important to assess chromosome 17 copy number to
nvestigate its possible implication in the clinical management of
atients with invasive primary breast cancer. Indeed, a recently
ublished study suggested that the presence of CEP17 alterations
ould identify a more aggressive subset of breast cancers that are
on-responsive to conventional therapy independently of HER2
[ Practice 211 (2015) 421–425
ampliﬁcation status [37]. However, other researchers believe that
polysomy 17 without HER2 ampliﬁcation do not predict response
to lapatinib in metastatic breast cancer [38]. Therefore, long-term
studies are required to determine the relationship between the role
of polysomy 17 in prognosis or the clinical response to trastuzumab
in breast cancer.
In summary, depending on which criterion is used for interpre-
tation, polysomy 17 is a crucial cause of misinterpretation of HER2
FISH results. Using the 2013 ASCO/CAP scoring criteria evaluate
HER2 status resulted in a signiﬁcantly higher number of HER2-
ampliﬁed cases being identiﬁed, especially IHC 2+ cases, which
identiﬁes more patients appropriate for targeted treatment. How-
ever, as there are no methods to determine chromosome 17 status
precisely, determining what CEP17 ampliﬁcation means in terms
of response to trastuzumab and anthracycline treatment requires
further study.
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